
According to a new market research report " Biosimilars Market By Type (Protein, Insulin, Human Growth Hormones, Granulocyte Colony-stimulating Factor (G-CSF), Interferons, Recombinant Glycosylated Proteins, Erythropoietin, Monoclonal Antibodies, Follitropin, Recombinant Peptides, Glucagon, Calcitonin), By Technology (, Mass Spectroscopy, Chromatography And Others), By Application (Oncology And Blood Diseases, Growth Hormone Deficiencies And Others), By Region - Global Industry Analysis, Size, Share, Growth, Trends, And Forecasts 2017-2022", published by MarketDataForecast. The Global Biosimilars Market was priced USD 4,760.0 million in 2016 and calculable to be growing at a CAGR of 26.87%, to achieve USD 19,154.5 million by 2022, within the mentioned forecast period. Biosimilars are derived from plants, bacteria, viruses, and animals. Biosimilars medicine is used in prevention and cure of varied diseases like growth hormone deficiency, chronic kidney disease, autoimmune diseases, arthritis, heart attacks, infectious disease, diabetes, cancer, and oncology. Rise in health care expenditure, is driving the demand for price effective therapeutics solution